Skip to content

XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Coronavirus – COVID-19 Program
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Media
    • Independent Research
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search
2012 Press Releases

XORTX Pharma Corp. Announces Publication of Phase II Proof of Concept Clinical Trial in Adolescent Hypertension.

  • November 29, 2012December 22, 2020
  • by aaronbb

CALGARY- Nov 29, 2012 – XORTX Pharma Corp. wishes to congratulate Dr. Beth Soletsky and Dr Daniel Fieg on the successful completion of their phase II clinical trial in adolescent hypertension entitled “Uric Acid Reduction Rectifies Prehypertension in Obese Adolescents” and publication of results in the prestigious journal Hypertension, 2012;60:1148.
› Read more

2012 Press Releases

XORTX Pharma Corp. Raises $450,000 in First Round Financing

  • October 15, 2012December 22, 2020
  • by aaronbb

CALGARY- Oct 15, 2012 – XORTX Pharma Corp. today announced the completion of a first round of financing. Dr. Allen Davidoff stated, “The company has taken a strong step forward with the completion of this first series of financing of XORTX Pharma Corp.
› Read more

2012 Press Releases

New Private Pharmaceutical Development Company Created – XORTX Pharma Corp.

  • August 24, 2012December 22, 2020
  • by aaronbb

CALGARY – August 24, 2012 – XORTX Pharma Corp. today announced the formation of a privately held Pharmaceutical Development Company built upon novel patents (intellectual property) in the fields of hypertension, insulin resistance, metabolic syndrome and diabetes prevention.

The  novel patents protect the use of all uric acid lowering agents (approved and in development)  for the treatment of the aforementioned disease entities. 
› Read more

Press Releases

  • XORTX Provides Corporate Update January 19, 2021
  • XORTX Grants Options January 12, 2021
  • XORTX Announces Private Placement January 7, 2021
  • XORTX Announces Grant of European Patent December 29, 2020
  • XORTX Announces Topline Results from Mount Sinai’s COVID-19 Clinical Study November 16, 2020

Archives

  • 2012 Press Releases 3
  • 2014 Press Releases 2
  • 2015 Press Releases 1
  • 2017 Press Releases 2
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress